HomeProductsBioactive CompoundsEpigeneticsEpigenetic Reader DomainCPI-0610 anhydrous
Chemical structure of CAS 1380087-89-7

CPI-0610 anhydrous

CAS No.1380087-89-7
MDL No.N/A
MFC20H16ClN3O2
MW365.80
InChI KeyGCWIQUVXWZWCLE-INIZCTEOSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1380087-89-7
Product NameCPI-0610 anhydrous

Biological Targets

BRD2·BRD4·BRDT·BRD3

Associated Conditions

neoplasm·myelofibrosis·primary myelofibrosis·tumour of cranial and spinal nerves·lymphoma·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression.

Molecular cancer • Vol. 22, Issue 1 • 2023
PMID: 37246217PMC: PMC10226260DOI: 10.1186/s12943-023-01792-0

BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer.

EBioMedicine • Vol. 60 • 2020
PMID: 32927276PMC: PMC7494677DOI: 10.1016/j.ebiom.2020.102988

Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials.

Journal of medicinal chemistry • Vol. 59, Issue 4 • 2016
PMID: 26815195DOI: 10.1021/acs.jmedchem.5b01882

Documentation